ECSP066534A - Formas de dosificacion de oxicodona de liberacion controlada, orales, una vez al dia - Google Patents

Formas de dosificacion de oxicodona de liberacion controlada, orales, una vez al dia

Info

Publication number
ECSP066534A
ECSP066534A EC2006006534A ECSP066534A ECSP066534A EC SP066534 A ECSP066534 A EC SP066534A EC 2006006534 A EC2006006534 A EC 2006006534A EC SP066534 A ECSP066534 A EC SP066534A EC SP066534 A ECSP066534 A EC SP066534A
Authority
EC
Ecuador
Prior art keywords
profiles
dosage forms
orals
vivo
day
Prior art date
Application number
EC2006006534A
Other languages
English (en)
Inventor
Stephen Hwang
Padmaja Shivanand
Nishit B Modi
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of ECSP066534A publication Critical patent/ECSP066534A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Se proveen formulaciones de oxicodona que producen perfiles de plasma en estado estable in vivo sustancialmente planos; los niveles de tolerancia relacionados con dichos perfiles y niveles de tolerancia relacionados con perfiles bifásicos no se muestran estadísticamente diferentes; los perfiles de plasma en estado estable in vivo sustancialmente planos se producen a través de formas de dosificación que tienen perfiles de liberación in vitro sustancialmente de orden cero; dichos perfiles de liberación producen bajos niveles de Cmax in vivo de dosis única los cuales pueden reducir la probabilidad de efectos secundarios adversos.
EC2006006534A 2003-10-29 2006-04-28 Formas de dosificacion de oxicodona de liberacion controlada, orales, una vez al dia ECSP066534A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51588003P 2003-10-29 2003-10-29

Publications (1)

Publication Number Publication Date
ECSP066534A true ECSP066534A (es) 2006-11-24

Family

ID=34549453

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006534A ECSP066534A (es) 2003-10-29 2006-04-28 Formas de dosificacion de oxicodona de liberacion controlada, orales, una vez al dia

Country Status (14)

Country Link
EP (1) EP1677798A2 (es)
JP (1) JP2007509979A (es)
KR (1) KR20060108690A (es)
CN (1) CN1933837A (es)
AU (1) AU2004285547A1 (es)
BR (1) BRPI0415639A (es)
CA (1) CA2546691A1 (es)
EC (1) ECSP066534A (es)
IL (1) IL175193A0 (es)
MA (1) MA28215A1 (es)
NO (1) NO20062398L (es)
RU (1) RU2006118323A (es)
WO (1) WO2005041968A2 (es)
ZA (1) ZA200604310B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
ES2599031T3 (es) 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
BR112012001466A2 (pt) 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9884022B2 (en) * 2010-04-07 2018-02-06 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
CN109789141B (zh) 2016-08-10 2022-08-26 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
MXPA04010769A (es) * 2002-04-29 2005-07-05 Alza Corp Metodos y formas de dosificacion para suministro controlado de oxicodona.
CA2487786A1 (en) * 2002-05-31 2003-12-11 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone

Also Published As

Publication number Publication date
AU2004285547A1 (en) 2005-05-12
BRPI0415639A (pt) 2006-12-12
JP2007509979A (ja) 2007-04-19
EP1677798A2 (en) 2006-07-12
CN1933837A (zh) 2007-03-21
RU2006118323A (ru) 2007-12-10
CA2546691A1 (en) 2005-05-12
WO2005041968A3 (en) 2006-06-22
KR20060108690A (ko) 2006-10-18
MA28215A1 (fr) 2006-10-02
WO2005041968A2 (en) 2005-05-12
IL175193A0 (en) 2008-04-13
NO20062398L (no) 2006-07-27
ZA200604310B (en) 2007-11-28

Similar Documents

Publication Publication Date Title
BRPI0415639A (pt) formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia
CR7500A (es) Formas de dosificacion de azitromicida con efectos secundarios reducidos
CR8767A (es) Indazoles sustituidos, composiciones que los contienen, procedimiento de preparacion y su uso
BR0309620A (pt) Métodos e formas de dosagem para liberação controlada de oxicodona
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
PA8616201A1 (es) Composiciones farmaceuticas de liberacion sostenida
SV2003001493A (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
BRPI0707612B8 (pt) vaso lacrado e formulações líquidas contidas no mesmo
PA8559501A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
ECSP055726A (es) Composición farmacéutica estabilizada que contiene excipientes básicos
AR047191A1 (es) Metodos de tratamiento de fibrosis hepatica
TW200640497A (en) Pharmaceutical formulations and methods of use
AR035293A1 (es) Composicion oftalmica.
CO6771406A2 (es) Una composición combinada
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
TW200744672A (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
EA200970353A1 (ru) Комбинированное лекарственное средство
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
DK1220676T3 (da) Forebyggelse af colorektal cancer
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
PL378106A1 (pl) Sposób wytwarzania zawierającej fibrat kompozycji farmaceutycznej w postaci tabletek oraz tabletki otrzymane tym sposobem